WO2000071560A1 - Techniques de modulation de l'activité de ribosomes procaryotes - Google Patents

Techniques de modulation de l'activité de ribosomes procaryotes Download PDF

Info

Publication number
WO2000071560A1
WO2000071560A1 PCT/US2000/012133 US0012133W WO0071560A1 WO 2000071560 A1 WO2000071560 A1 WO 2000071560A1 US 0012133 W US0012133 W US 0012133W WO 0071560 A1 WO0071560 A1 WO 0071560A1
Authority
WO
WIPO (PCT)
Prior art keywords
binding
compound
modulation
ribosomal
polynucleotide
Prior art date
Application number
PCT/US2000/012133
Other languages
English (en)
Inventor
Lisa Anne Hegg
Therese Anne Sterner
Donna M. FERGUSON
Kelvin C. Nurse
Original Assignee
Smithkline Beecham Corporation
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation, Smithkline Beecham Plc filed Critical Smithkline Beecham Corporation
Priority to EP00946758A priority Critical patent/EP1181305A4/fr
Priority to JP2000619815A priority patent/JP2003523729A/ja
Publication of WO2000071560A1 publication Critical patent/WO2000071560A1/fr
Priority to US10/869,759 priority patent/US20050159377A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)

Abstract

Cette invention, qui a trait à de nouveaux polynucléotides identifiés ainsi qu'aux interactions de ces polynucléotides avec des polypeptides, concerne également leur production et l'usage qui en est fait, ainsi que leurs variants, leurs agonistes et leurs antagonistes. A cet égard et à d'autres, l'invention porte, notamment, sur des polynucléotides utilisés pour identifier des composés modulant l'activité de ribosomes procaryotes.
PCT/US2000/012133 1999-05-20 2000-05-04 Techniques de modulation de l'activité de ribosomes procaryotes WO2000071560A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP00946758A EP1181305A4 (fr) 1999-05-20 2000-05-04 Techniques de modulation de l'activit de ribosomes procaryotes
JP2000619815A JP2003523729A (ja) 1999-05-20 2000-05-04 原核生物リボソームの活性を変調する方法
US10/869,759 US20050159377A1 (en) 2000-05-04 2004-06-16 Methods of modulating activity of prokaryotic ribosomes

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US13497399P 1999-05-20 1999-05-20
US60/134,973 1999-05-20
US13783799P 1999-06-07 1999-06-07
US60/137,837 1999-06-07
US13909599P 1999-06-14 1999-06-14
US60/139,095 1999-06-14

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/869,759 Continuation US20050159377A1 (en) 2000-05-04 2004-06-16 Methods of modulating activity of prokaryotic ribosomes

Publications (1)

Publication Number Publication Date
WO2000071560A1 true WO2000071560A1 (fr) 2000-11-30

Family

ID=27384650

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/012133 WO2000071560A1 (fr) 1999-05-20 2000-05-04 Techniques de modulation de l'activité de ribosomes procaryotes

Country Status (3)

Country Link
EP (1) EP1181305A4 (fr)
JP (1) JP2003523729A (fr)
WO (1) WO2000071560A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018750A2 (fr) * 2001-08-22 2003-03-06 Isis Pharmaceuticals, Inc. Sites d'interaction moleculaire de l'arn ribosomal 23s et procedes de modulation de ces derniers
WO2003082260A2 (fr) * 2002-03-28 2003-10-09 Sandoz Ag Traitement de la tuberculose
WO2006070671A1 (fr) * 2004-12-27 2006-07-06 Kyorin Pharmaceutical Co., Ltd. Derive de la mutiline substitue en position 12
WO2010045133A1 (fr) * 2008-10-13 2010-04-22 3M Innovative Properties Company Procédés de détection de staphylococcus aureus
US9701628B2 (en) 2014-01-22 2017-07-11 Nabriva Therapeutics Ag 12-epi pleuromutilins

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BROSIUS J. ET AL.: "Complete nucleotide sequence of a 23S ribosomal RNA gene from escherichia coli", PROC. NATL. ACAD. SCI. USA, vol. 77, no. 1, January 1980 (1980-01-01), pages 201 - 204, XP002931146 *
DATABASE GENBANK ON NCBI, US NATIONAL LIBRARY OF MEDICINE (BETHESDA, MD, USA); March 1991 (1991-03-01), BROSIUS J. ET AL.: "Complete nucleotide sequence of a 23S ribosomal RNA gene from Escherichia coli", XP002908790 *
DORNHELM P. ET AL.: "The effects of tiamulin, a semisynthetic pluromutilin derivative, on bacterial polypeptide chain initiation", EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 91, no. 2, pages 465 - 473, XP000950040 *
HOGENAUER G. ET AL.: "Ribosomal binding region for the antibiotic tiamulin: stoichiometry, subunit location and affinity for various analogs", ANTIMICROBIAL AGENTS CHEMOTHERAPY, vol. 19, no. 2, February 1981 (1981-02-01), pages 260 - 265, XP002930969 *
PROC. NATL. ACAD. SCI. USA, vol. 77, no. 1, 1980, pages 201 - 204 *
See also references of EP1181305A4 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018750A2 (fr) * 2001-08-22 2003-03-06 Isis Pharmaceuticals, Inc. Sites d'interaction moleculaire de l'arn ribosomal 23s et procedes de modulation de ces derniers
WO2003018750A3 (fr) * 2001-08-22 2003-11-13 Isis Pharmaceuticals Inc Sites d'interaction moleculaire de l'arn ribosomal 23s et procedes de modulation de ces derniers
WO2003082260A2 (fr) * 2002-03-28 2003-10-09 Sandoz Ag Traitement de la tuberculose
WO2003082260A3 (fr) * 2002-03-28 2004-03-25 Sandoz Ag Traitement de la tuberculose
JP2005529088A (ja) * 2002-03-28 2005-09-29 サンド・アクチエンゲゼルシヤフト プルロムチリン誘導体を使用する結核症治療
EP1875903A1 (fr) 2002-03-28 2008-01-09 Nabriva Therapeutics Forschungs GmbH Traitement de la tuberculose utilisant les dérivés de pleuromutiline
JP4708708B2 (ja) * 2002-03-28 2011-06-22 ナブリバ・セラピユーテイクス・アクチエンゲゼルシヤフト プルロムチリン誘導体を使用する結核症治療
US8088823B2 (en) 2002-03-28 2012-01-03 Nabriva Therapeutics Ag Tuberculosis treatment using pleuromutilin derivatives
WO2006070671A1 (fr) * 2004-12-27 2006-07-06 Kyorin Pharmaceutical Co., Ltd. Derive de la mutiline substitue en position 12
WO2010045133A1 (fr) * 2008-10-13 2010-04-22 3M Innovative Properties Company Procédés de détection de staphylococcus aureus
US9701628B2 (en) 2014-01-22 2017-07-11 Nabriva Therapeutics Ag 12-epi pleuromutilins

Also Published As

Publication number Publication date
EP1181305A4 (fr) 2002-09-18
EP1181305A1 (fr) 2002-02-27
JP2003523729A (ja) 2003-08-12

Similar Documents

Publication Publication Date Title
EP1181305A1 (fr) Techniques de modulation de l'activit de ribosomes procaryotes
US20050159377A1 (en) Methods of modulating activity of prokaryotic ribosomes
US6110723A (en) Yfii pseudouridine synthase
US6365387B1 (en) fabG
US6448038B1 (en) BirA from staphylococcus aureus
US6287810B1 (en) Polynucleotides encoding an undercaprenyl diphosphate synthase of staphylococcus aureus
US20060223082A1 (en) Map
US6352840B1 (en) pskG
WO2002011673A2 (fr) Procedes permettant de moduler l'activite de la dxr
US6406889B1 (en) 509hk
US6352843B1 (en) YsxC from Staphylococcus aureus
US6194174B1 (en) Histidine kinase, 636 HK, of staphylococcus aureus
US20020119520A1 (en) FabZ
US6107058A (en) ispA from Staphylococcus aureus
US6197546B1 (en) PcrA Helicase of Staphylococcus aureus
US6326167B1 (en) TktA from Streptococcus pneumoniae
WO2001030806A1 (fr) Polynucleotides et polypeptides intervenant dans la biologie des films biologiques, et leurs utilisations
US6238885B1 (en) Histidine kinase
US6346395B1 (en) Nucleic acids encoding Streptococcus pneumoniae FabG
US6280990B1 (en) dnaE
US6251633B1 (en) Polynucleotides encoding Staphylococcus aureus FtsA polypeptide
US6277597B1 (en) kdtB
US6221631B1 (en) tktA
US6346396B1 (en) MurA
US6316211B1 (en) ThdF

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000946758

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10019369

Country of ref document: US

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 619815

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2000946758

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000946758

Country of ref document: EP